Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with paclitaxel

Clinical Cancer Research

Volumn 20, Issue 9, 2014, Pages 2466-2475

  Abraham, Jean E ^a,b,d   Guo, Qi ^a   Dorling, Leila ^a   Tyrer, Jonathan ^a   Ingle, Susan ^b   Hardy, Richard ^b   Vallier, Anne Laure ^b   Hiller, Louise ^e   Burns, Russell ^b   Jones, Linda ^b   Bowden, Sarah J ^f   Dunn, Janet A ^e   Poole, Christopher J ^e   Caldas, Carlos ^b,c,d   Pharoah, Paul P D ^a   Earl, Helena M ^b,d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d Cambridge Experimental Cancer Medicine Centre   (United Kingdom)

^e UNIVERSITY OF WARWICK   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; TAXANE; TAXOID;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; EARLY CANCER; ETHNIC GROUP; EUROPEAN; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; NEUROPATHOLOGY; PRIORITY JOURNAL; SENSORY NEUROPATHY; SINGLE NUCLEOTIDE POLYMORPHISM; TAXANE RELATED SENSORY NEUROPATHY; ADULT; AGED; BREAST NEOPLASMS; COMPLICATION; FEMALE; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; ODDS RATIO; PATHOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; TAXOIDS;

EID: 84899708847     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-3232     Document Type: Article

References (44)

1. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010;9: 790-803.
2. Baldwin RM,Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, et al. A genome-wide association study identifies novel loci for paclitaxelinduced peripheral neuropathy in CALGB 40101. Clin Cancer Res 2012;18:5099-109.
3. Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 2011;125:767-74.
4. Schneider BP, Li L, Miller K, Flockhart D, Radovich M, Hancock BA, et al. Genetic associations with taxane-induced neuropathy by genome wide association study (GWAS) in E5103. J Clin Oncol 2011;29:(suppl 15; abstract 1000).
5. Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT) an open-label phase III randomised controlled trial. Lancet 2009;373:1681-92.
6. Osmani K, Vignes S, Aissi M, Wade F, Milani P, Levy BI, et al. Taxaneinduced peripheral neuropathy has good long-term prognosis: a 1-to 13-year evaluation. J Neurol 2012;259:1936-43.
7. Hagiwara H, Sunada Y. Mechanism of taxane neurotoxicity. Breast Cancer 2004;11:82-5.
8. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 2000;406:25-32.
9. Watters JW, Kraja A, Meucci MA, Province MA, McLeod HL. Genomewide discovery of loci determining chemotherapy cytotoxicity. Proc Natl Am Sci 2004;101:11809-14.
10. Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ. Traitassociated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet 2010;6:e1000888.
11. Leandro-Garcia LJ, Inglada-Perez L, Pita G, Hjerpe E, Leskela S, Jara C, et al. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced sensory neuropathy. J Med Genet 2013;50:599-605.
12. Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 2006;355: 1851-62.
13. Poole CJ, Hiller L, Howard HC, Dunn JA, Canney P, Wardley AM, et al. tAnGo: a randomized phase III trial of gemcitabine (gem) in paclitaxelcontaining, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC). J Clin Oncol 2008;26:15S:(abstract 506).
14. Earl HM, Vallier AL, Hiller L, Fenwick N, Young J, Iddawela M, et al. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 22 factorial randomised phase 3 trial. Lancet Oncol 2013;15:201-12.
15. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharm Ther 2012;92:414-7.
16. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in ovarian cancer. J Clin Oncol 2007;25:4528-35.
17. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. J Pharm Sci 2008;97:2045-8.
18. Leskela S, Jara C, Leandro-Garcia LJ, Martínez A, García-Donas J, Hernando S, et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J 2011;11:121-9.
19. Rizzo R, Spaggiari F, Indelli M, Lelli G, Baricordi OR, Rimessi P, et al. Association of CYP1B1 with hypersensitivity induced by Taxane therapy in breast cancer patients. Breast Cancer Res Treat 2010;124: 593-8.
20. Ofverholm A, Einbeigi Z, Manouchehrpour S, Albertsson P, Skrtic S, Enerback C. The ABCB1 3435 T allele does not increase the risk of paclitaxel-induced neurotoxicity. Oncol Lett 2010;1:151-4.
21. Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, et al. CYP2C83 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol 2013;00:1-7.
22. Bergmann TK, Green H, Brasch-Andersen C, Mirza MR, Herrstedt J, Hølund B, et al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharm 2011;67:693-700.
23. Bergmann TK, Brasch-Andersen C, Green H, Mirza MR, Skougaard K, Wihl J, et al. Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer. Basic Clin Pharm Toxicol 2011;110:199-204.
24. Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A, et al. Association of ABCB1 genotypes with paclitaxelmediated peripheral neuropathy and neutropenia. Eur J Cancer 2006;42:2893-6.
25. Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, et al. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen independent prostate cancer treated with docetaxel. Clin Cancer Res 2008;14:4543-9.
26. Chang H, Rha SY, Jeung H-C, Im C-K, Ahn JB, Kwon WS, et al. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol 2009;20:272-7.
27. Mir O, Alexandre J, Tran A, Durand JP, Pons G, Treluyer JM, et al. Relationship between GSTP1 Ile105Val polymorphism and docetaxelinduced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Ann Oncol 2009;20:736-40.
28. Sucheston LE, Moore HCF, Ciupak GL, Zirpoli G, Liu S, Barlow WE, et al. Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat 2011;130:993-1002.
29. Leandro-Garcia LJ, Leskela S, Jara C, Green H, Avall-Lundqvist E, Wheeler HE, et al. Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin Cancer Res 2012;18:4441-8.
30. Sankararaman S, Sridhar S, Kimmel G, Halperin E. Estimating local ancestry in admixed populations. Am J Hum Genet 2008;82:290-303.
31. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, et al. The 1000 Genomes Project Consortium: an integrated map of genetic variation from 1,092 human genomes. Nature 2012; 491:56-65.
32. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genomewide association studies. Nat Genet 2006;38:904-9.
33. Howie B, Marchini J, Stephens M. Genotype imputation with thousands of genomes. G3: Genes, Genomes, Genetics 2011;1:457-70.
34. Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of genomes. Nat Methods 2012;9:179-81.
35. Pharoah PDP, Tyrer J, Dunning AM, Easton DF, Ponder BAJSEARCH Investigators. Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet 2007;3:e42.
36. Tyrer J, Pharoah PDP, Easton DF. The admixture maximum likelihood test: a novel experiment-wise test of association between disease and multiple SNPs. Genet Epidemiol 2006;30:636-43.
37. Little J, Higgins JPT, Ioannidis JP, Moher D, Gagnon F, von Elm E, et al. STrengthening the REporting of Genetic Association Studies (STREGA)-an extension of the STROBE statement. PLoS Med 2009;6:e1000022.
38. Miao H, Wang B. EphA receptor signalling-complexity and emerging themes. Semin Cell Dev Biol 2012;23:16-25.
39. Munro KM, Perreau VM, TurnleyAM. Differential gene expression in the EphA4 knockout spinal cord and analysis of the inflammatory response following spinal cord injury. PLoS ONE 2012;7:e37635.
40. de Graan AJ, Elens L, Sprowl JA, Sparreboom A, Friberg LE, van der Holt B, et al. CYP3A4-22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin Cancer Res 2013;19;3316-24.
41. Tegze B, Szallasi Z, Haltrich I, Penzvalto Z, Toth Z, Liko I, et al. Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance. PLoS ONE 2012;7: e30804.
42. Wakefield J. Reporting and interpretation in genome-wide association studies. Int J Epidemiol 2008;37:641-53.
43. Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, et al. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res 2012;19;1-9.
44. Huang HQ, Brady MF, Cella D, Fleming G. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 2007;17:387-93.